CircMAP3K5 promotes cardiomyocyte apoptosis in diabetic cardiomyopathy by regulating miR-22-3p/DAPK2 Axis

Ming Shen1,2, Yuanbin Wu3, Libing Li1

  • 1Department of Cardiovascular Surgery, The First Medical Center of PLA General Hospital, Beijing, China.

Journal of Diabetes
|September 22, 2023
PubMed

Insights

Circular RNA MAP3K5 (circMAP3K5) promotes diabetic cardiomyopathy by increasing cardiomyocyte apoptosis via the miR-22-3p/DAPK2 pathway. Targeting circMAP3K5 offers a potential therapeutic strategy for diabetic heart disease.

Area of Science:

  • Cardiovascular Research
  • Molecular Biology
  • Genetics

Background:

  • Diabetic cardiomyopathy (DCM) is a severe complication of diabetes with no effective treatments.
  • Circular RNAs (circRNAs) are implicated in cardiac diseases, but the role of circRNA MAP3K5 (circMAP3K5) in DCM is unknown.

Purpose of the Study:

  • To investigate the role and mechanism of circMAP3K5 in diabetic cardiomyopathy.
  • To explore circMAP3K5 as a potential therapeutic target for DCM.

Main Methods:

  • Microarray analysis identified circMAP3K5 in DCM rat hearts.
  • In vitro studies used high glucose-induced H9c2 cardiomyocytes to assess circMAP3K5 function.
  • Mechanistic studies involved assessing circMAP3K5's interaction with miR-22-3p and DAPK2.

Main Results:

  • CircMAP3K5 expression is upregulated in DCM and by high glucose, promoting cardiomyocyte apoptosis.
  • Depletion of circMAP3K5 reduced high glucose-induced apoptosis.
  • CircMAP3K5 acts as a sponge for miR-22-3p, upregulating DAPK2 expression.

Conclusions:

  • CircMAP3K5 promotes high glucose-induced cardiomyocyte apoptosis by regulating the miR-22-3p/DAPK2 axis.
  • CircMAP3K5 is a conserved noncoding RNA and a potential therapeutic target for DCM.
Abstract